Alzheimer's disease (AD) stands as the predominant form of dementia, presenting significant
and escalating global challenges. Its etiology is intricate and diverse, stemming from a …

Background Tauopathies are a class of neurodegenerative disorders characterized by
neuronal and/or glial tau-positive inclusions. Main body Clinically, tauopathies can present …

Alzheimer's disease (AD) is the most common neurodegenerative disease in the elderly
worldwide. However, the complexity of AD pathogenesis leads to discrepancies in the …

Tau protein is involved in various cellular processes, including having a canonical role in
binding and stabilization of microtubules in neurons. Tauopathies are neurodegenerative …

Alzheimer disease (AD) is the most common cause of dementia in older individuals. AD is
characterized pathologically by amyloid-β (Aβ) plaques and tau neurofibrillary tangles in the …

Alzheimer's Disease (AD) contributes to most cases of dementia. Its prominent
neuropathological features are the extracellular neuritic plaques and intercellular …

Alzheimer's disease (AD) research has entered a new era with the recent positive phase 3
clinical trials of the anti-Aβ antibodies lecanemab and donanemab. Why did it take 30 years …

Background. Aducanumab, a new monoclonal antibody that targets β‐amyloid aggregates,
has been granted conditional approval by the US FDA for treatment of mild Alzheimer's …

Alzheimer's disease (AD) is a progressive neurodegenerative disorder and a major
contributor to dementia cases worldwide. AD is clinically characterized by learning, memory …

Protein kinases (PKs) have emerged as one of the most intensively investigated drug targets
in current pharmacological research, with indications ranging from oncology to …